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Abstract In this study we demonstrate that the multidrug
resistance (MDR) modulator PSC 833 is a potent agonist of
ceramide metabolism. When added with [3H]serine or
[3H]palmitic acid to the culture medium of MCF-7 cells, PSC
833, in a dose-responsive fashion (1^10 WM), increased the levels
of [3H]ceramide as much as 16-fold over control. The actual
increase in ceramide mass was verified by thin-layer chromato-
graphic chars. Cellular sphingomyelin radioactivity did not
decrease during treatment, indicating that PSC 833 does not
elicit ceramide formation through a sphingomyelinase pathway.
Inclusion of fumonisin B1, an inhibitor of ceramide synthase,
blocked formation of ceramide by PSC 833. The results of cell
proliferation assays demonstrated a clear correlation between
PSC 833 elicitation of ceramide formation and increased
cytotoxicity. The MDR modulator and chemical cousin of
PSC 833, cyclosporin A, had little impact on cellular ceramide
formation. At a concentration of 2.5 WM, cyclosporin A and PSC
833 treatment increased ceramide formation by 20% and 7.5-
fold, respectively. These results reveal a new action of PSC 833
which may contribute to its potency as a drug resistance
modulator.
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1. Introduction
Multidrug resistance (MDR) is a major cause of cancer
treatment failure. Overexpression of P-glycoprotein (P-gp), a
170 kDa plasma membrane protein that functions as a drug
e¥ux pump for chemotherapeutic agents, is one of the most
consistent alterations of the MDR phenotype [1,2]. P-gp ac-
tion lowers the e¡ective intracellular drug concentration there-
by limiting the accumulation of therapeutic agents. Many of
the antineoplastic agents involved in MDR are quite diverse
and represent an important segment of the chemotherapy ar-
mamentarium. The drugs include anthracyclines such as dox-
orubicin and daunorubicin, etoposide, paclitaxel (taxol), and
vinca alkaloids such as vinblastine and vincristine.
Numerous agents have been studied in an e¡ort to over-
come MDR; however, a major challenge in cancer chemo-
therapy today is to understand the molecular mechanisms
by which MDR modulators, e.g. tamoxifen, PSC 833, vera-
pamil, reverse drug resistance. Works have shown that MDR
modulators bind directly to P-gp and thus interfere with bind-
ing and export of anticancer agents [3^5]. This appears to be
the most prominent mechanism for restoring cytotoxicity in
an otherwise resistant setting. Our recent studies with MDR
modulators demonstrate that these agents also have an impact
on glycolipid metabolism [6,7], namely inhibition of ceramide
glycosylation which results in a lowering of cellular glucocer-
ebroside (glucosylceramide) levels. Because of the involvement
of ceramide in the potentiation of apoptosis [8] and the inter-
est in apoptosis as a mechanism important for cytotoxic re-
sponse to anticancer agents [9], we sought to determine
whether some MDR modulators also in£uence ceramide me-
tabolism downstream from the glycosylation step.
Two cyclosporin derivatives, cyclosporin A and PSC 833,
have been shown to be potent MDR reversing agents [10^12].
Direct interaction between PSC 833 and P-gp has been dem-
onstrated [13], and it is this binding that is believed to be the
basis for modulation of chemotherapy resistance. Our studies
here demonstrate that PSC 833 has a profound e¡ect on cer-
amide formation, whereas the chemical analog, cyclosporin A,
is without in£uence. Further, the elevation of ceramide, in
response to PSC 833 treatment, correlated with an increase
in cell death. These data suggest that the MDR modulator
PSC 833 has a P-gp independent mechanism of action which
may account for its potency.
2. Materials and methods
2.1. Materials
MCF-7 (human breast cancer) cells were provided by Dr. Kenneth
Cowan and Dr. Merrill Goldsmith, National Cancer Institute, Bethes-
da, MD. Cyclosporin A and PSC 833, [3P-keto-Bmt-1]-[Val-2]-cyclo-
sporin, were gifts from Novartis, East Hanover, NJ. [9,10-3H]Palmitic
acid (50 Ci/mmol) was from Dupont NEN, Boston, MA, and
[3H]serine (20 Ci/mmol) was purchased from American Radiolabeled
Chemicals, St. Louis, MO. Ceramide and sphingomyelin (brain-de-
rived) were purchased from Avanti Polar Lipids, Alabaster, AL.
TLC plates (Silica gel G) were from Analtech, Newark, DE, and
FBS was purchased from Hyclone, Logan, UT. RPMI-1640 medium
was purchased from Gibco-BRL, Grand Island, NY. Tissue culture
plasticware was from Corning, Cambridge, MA, and water-compat-
ible liquid scintillation cocktail, Ecolume, was purchased from ICN
Biomedicals, Costa Mesa, CA.
2.2. Cell culture
Cells were grown in RPMI 1640 medium containing 10% FBS (v/v),
100 units/ml penicillin, 100 Wg/ml streptomycin, and 584 mg/l L-glu-
tamine and subcultured as described [7]. The FBS content of the
medium was lowered to 5% for all experiments. Stock solutions of
PSC 833 (10 mM) were prepared in ethanol in 1-dram glass vials with
Te£on-lined screw caps and stored at 320‡C. Culture medium con-
taining PSC 833 was prepared just prior to use. Ethanol vehicle was
present in all controls.
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2.3. Cell radiolabeling and lipid analysis
Cultures, during log phase growth, were treated with PSC 833 and
supplemented with [3H]palmitic acid (1.0 WCi/ml medium) or
[3H]serine (2.0 WCi/ml) for the times speci¢ed. Experiments were ter-
minated by removing the medium, rinsing the monolayers three times
with cold phosphate bu¡ered saline, and scraping the cells in ice-cold
methanol containing 2% acetic acid. Lipid extraction [14] was contin-
ued in 1-dram glass vials with screw caps. After vortex mixing and
centrifugation the lower phase of the biphasic extraction containing
total cellular lipids was removed and taken to dryness under a stream
of nitrogen. Lipids were dissolved in chloroform/methanol (2:1, v/v),
usually 50^100 Wl, for analysis by TLC.
Ceramide was resolved from total lipids by TLC in a solvent system
containing chloroform/acetic acid (90:10, v/v), and sphingomyelin was
resolved in a solvent system containing chloroform/methanol/acetic
acid/water (50:30:7:4, v/v). Glucosylceramide was separated from
other lipids by TLC in chloroform/methanol/ammonium hydroxide
(70:20:4, v/v). Commercial lipid standards were co-applied to the
TLC plate origins, and lipid identi¢cation was done by comparing
migration after iodine staining. Areas of the chromatogram contain-
ing the radiolabeled lipid were scraped into plastic mini scintillation
vials containing 0.5 ml water followed by 4.5 ml Ecolume, and tritium
analysis was by LSC.
To char unlabeled cellular lipids for mass analysis, following devel-
opment of the chromatogram in the appropriate solvent system, the
plates were dried, sprayed with 30% sulfuric acid, and heated in an
oven for 20 min at 180‡C. For mass comparisons of ceramide in
control and PSC 833 treated cells, aliquots of 100^200 Wg total lipid
(by weight) were adequate. To assess ceramide by an alternative meth-
od, total cell lipids were base-hydrolyzed (mild alkaline hydrolysis) in
0.1 N KOH in methanol for 1 h at 37‡C. Lipids were re-extracted [14]
and analyzed by TLC either in the above described solvent system or
in a system containing hexane/diethyl ether/acetic acid (50:50:1, v/v).
2.4. Cytotoxicity assay
Cells (2000/well/0.1 ml medium) were seeded into 96-well plates and
after 24 h, treatment medium (0.1 ml) containing PSC 833 was added.
After 4 days, cell viability was determined spectrophotometrically (V
490, Molecular Devices, Emax microplate reader, Sunnyville, CA)
using the Promega Titer 96 Aqueous cell proliferation assay kit.
This assay is based on the capacity of viable cells to convert a tetra-
zolium derivative to a water-soluble formazan that absorbs light at
490 nm.
3. Results
In previous work we demonstrated that modulators of
MDR in£uence ceramide metabolism by retarding the glyco-
sylation step that forms glucocerebrosides [6,7]. PSC 833 was
however di¡erent from tamoxifen, verapamil, and cyclosporin
A in that glucocerebrosides such as glucosylceramide in-
creased in response to PSC 833 treatment [15]. This ¢nding
led us to investigate the in£uence of PSC 833 on the metab-
olism of ceramide, the immediate precursor of glucocerebro-
sides. The data in Table 1 show that PSC 833 treatment of
MCF-7 cells elicited a 16-fold increase (over control) in levels
of [3H]ceramide after a 48 h exposure. Based on total lipid
tritium per culture, ceramide accounted for 0.45 and 7.3% of
total lipid radioactivity in control and PSC 833 treated cells,
respectively. Results are also presented from experiments us-
ing [3H]serine, a more speci¢c sphingolipid precursor that
does not radiolabel the aliphatic chains. As shown, PSC 833
(5.0 WM) elicited a s 6-fold increase in cellular ceramide after
only 24 h (Table 1). PSC 833, as previously reported for
adriamycin resistant breast cancer cells [15], increased gluco-
sylceramide in MCF-7 cells by 2.5-fold (Table 1). Radioactiv-
ity in sphingomyelin, which has been shown by many inves-
tigators to be the source of agonist-induced ceramide
formation, was not depleted in response to PSC 833. On the
contrary, radioactivity in cellular sphingomyelin increased by
50% (Table 1).
Although [3H]palmitic acid has reached steady state after a
48 h incubation and tritium levels would be re£ective of actual
lipid mass changes, we analyzed cellular lipids by TLC char-
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Table 1
The in£uence of PSC 833 on lipid metabolism in MCF-7 cells
Lipid Cell incubation conditions
3 PSC 833 + PSC 833
Ceramide 2 270 þ 270a 36 410 þ 603
Ceramideb 4 637 þ 49 29 848 þ 1 707
Glucosylceramide 8 957 þ 364 22 046 þ 280
Sphingomyelin 41 560 þ 3,219 62 918 þ 7 009
MCF-7 cells were cultured for 48 h in the presence of [3H]palmitic acid and PSC 833 (10 WM), after which time total cell lipids were extracted [14]
and [3H]ceramide, [3H]glucosylceramide, and [3H]sphingomyelin were quantitated by TLC and LSC. Data represent the mean þ S.D. Experiments
were repeated two to three times with similar results.
aNumbers represent cpm in the speci¢ed lipid class per 500 000 cpm total lipid tritium.
bThese data were obtained from cells labeled for 24 h with [3H]serine and co-cultured in the absence or presence of PSC 833 (5.0 WM).
Fig. 1. Thin-layer chromatographic char of lipids isolated from cells
treated with PSC 833. MCF-7 cells were treated with PSC 833
(5.0 WM) for 24 h. The total lipid extract (200 Wg aliquot) was ap-
plied to TLC plates for ceramide resolution. Visualization was by
charring. Lane 1, control cells; lane 2, PSC 833 treatment; lane 3,
commercial ceramide standard.
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ring. The chromatogram (Fig. 1) shows the changes in ceram-
ide mass after a 24 h exposure of cells to PSC 833. In control
cells (Fig. 1, lane 1), ceramide was barely detectable. In con-
trast, cellular ceramide mass increased markedly in cells that
were treated with PSC 833 (Fig. 1, lane 2). The two central
spots (lane 2), which correspond to the migration of the com-
mercial standard doublet (Fig. 1, lane 3), represent ceramide
molecular species di¡ering in their aliphatic constituents. The
lower-most spot (lane 2) has been identi¢ed as monoacylglyc-
erol. The upper-most spot was also present in the commercial
brain derived ceramide standard; however, at the concentra-
tion applied to lane 3, it is not visible. Subjecting a sample of
total lipid to mild alkaline hydrolysis followed by TLC anal-
ysis gave identical ceramide results as the char shown in Fig.
1. These alkaline conditions hydrolyze ester-linked acyl
groups, removing possible contaminates, while leaving the
amide linkage of ceramide intact.
To determine whether ceramide generation occurs in a dose
responsive manner, cells were exposed to increasing concen-
trations of PSC 833. As shown in Fig. 2, cellular [3H]ceramide
increased with increasing PSC 833. At a concentration of
1.0 WM, PSC 833 enhanced cellular [3H]ceramide content by
4-fold, and at 5.0 WM PSC 833, cellular [3H]ceramide content
was s 9-fold that of control. In sharp contrast, treatment of
cells with cyclosporin A (2.5 and 5.0 WM), which is very sim-
ilar in structure to PSC 833, elicited a 0.23- and 0.51-fold
increase, respectively, in [3H]ceramide (Fig. 2).
Ceramide has been shown to be toxic in numerous cell
systems [8,16,17], and we have shown that PSC 833 pro-
foundly elevates cellular ceramide levels. Taking this into ac-
count it was reasoned that the PSC 833/ceramide response
should impact cell viability. The data of Fig. 3 show that
PSC 833 was cytotoxic, and cytotoxicity was positively corre-
lated with increasing drug concentration. At 10 WM PSC 833,
cell survival was reduced to 20%. The IC50 (amount of drug
that causes 50% cell death) for PSC 833 was approximately
5.0 WM, and at this concentration cell ceramide levels were
9-fold greater than control (Fig. 2). A comparison of Figs. 2
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Fig. 3. In£uence of PSC 833 concentration on cell viability. MCF-7
cells, seeded at 2000 cells/well in 96-well plates, were treated for
4 days with PSC 833 at the concentrations indicated. Cell viability
was determined spectrophotometrically as described in Section 2.
Each data point represents the average þ S.D. of six replicate wells.
Fig. 4. E¡ect of fumonisin B1 on ceramide formation by PSC 833.
MCF-7 cells in 6 cm tissue culture dishes were treated when approx-
imately 70% con£uent with PSC 833 (5.0 WM) and given
[3H]palmitic acid in the absence or presence of FB1 (50 WM) for 2 h.
FB1 was dissolved in water. Cellular lipids were analyzed for
[3H]ceramide content by TLC and LSC. Drugs had no in£uence on
the uptake of palmitic acid.
Fig. 2. In£uence of PSC 833 concentration on ceramide formation
in MCF-7 cells. Cells were treated for 48 h with PSC 833 at the
concentrations indicated. The culture medium contained [3H]palmitic
acid (1.0 WCi/ml). [3H]Ceramide was analyzed in the total lipid ex-
tract by TLC and LSC. PSC 833 at all concentrations shown did
not in£uence the cellular uptake of [3H]palmitic acid. Data points
represent the average of duplicate cultures; variability was 6 10%.
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and 3 shows a strong association between increasing cellular
ceramide levels (Fig. 2) and a decrease in cell survival (Fig. 3).
These data suggest that PSC 833 is cytotoxic through a cer-
amide related event.
Table 1 shows that PSC 833, while having a marked e¡ect
on ceramide formation, had little in£uence on sphingomyelin
metabolism. To determine if PSC 833 is a¡ecting ceramide
metabolism via synthesis, the in£uence of the ceramide syn-
thase inhibitor, FB1, was evaluated. Pretreating MCF-7 cells
with FB1 severely inhibited the promotion of ceramide for-
mation by PSC 833 (Fig. 4). When PSC 833 and FB1 were
present simultaneously, levels of [3H]ceramide were reduced
from approximately 30 000 cpm (PSC 833 only) to 8000 cpm.
4. Discussion
The mechanism of action of the MDR modulator PSC 833
is believed to involve inhibition of drug e¥ux by P-gp
[13,18,19]. However, the speci¢c sites of action and the mech-
anisms by which MDR modulators reverse chemotherapy re-
sistance continue to be a topic of interest. Here we show for
the ¢rst time, using a cell line that is P-gp de¢cient, that PSC
833 has a profound impact on ceramide formation. These
experiments employed PSC 833 as the sole drug; therefore,
the complexities of combination chemotherapy were not in-
volved in the biochemistry of the ceramide response. The in-
crease in cell ceramide caused by PSC 833 paralleled a de-
crease in cell survival. This suggests that the action of PSC
833 is, in part, related to the e¡ects of this drug on the me-
tabolism of ceramide. Cyclosporin A, which structurally is
very similar to PSC 833, by contrast was a weak agonist of
ceramide formation (Fig. 2).
Ceramide is an important e¡ector of apoptosis and a sec-
ond messenger of cellular di¡erentiation [8,20]. Thus, agents
that elicit ceramide formation are potentially important in cell
regulatory processes. Ceramide generation can be promoted
by a myriad of agents including anti-IgM [16], ionizing radi-
ation [21], and Fas/Apo-1 [22]. In most instances, ceramide
formation is triggered via enzymatic degradation of sphingo-
myelin [8,16,21,22]. Our results di¡er in that ceramide is not
generated, in response to PSC 833, at the expense of sphingo-
myelin (Table 1). These data suggest that PSC 833 impacts
ceramide synthesis. To further test this hypothesis, FB1, a
ceramide synthase inhibitor, was employed. The data showed
that PSC 833 elicited ceramide generation was blocked by
FB1. This strongly argues against a sphingomyelinase path-
way of ceramide genesis in the PSC 833 response.
There exist questions regarding the di¡erential mechanisms
of actions and potencies of cyclosporin A and PSC 833 as
MDR modulators. PSC 833 has been shown to be more po-
tent in reversing MDR [11,12] and whereas both PSC 833 and
cyclosporin A bind to P-gp, only the latter is transported [13].
In comparing cyclosporin A and PSC 833, we show that
cyclosporin A had little in£uence on cellular ceramide forma-
tion. The two MDR modulators di¡er only slightly in struc-
ture [13] ; therefore, the ceramide response must be closely
related to the chemistry of these agents. The question arises
whether PSC 833 exerts in£uence on ceramide metabolism
through interaction with P-gp. Although we are only begin-
ning to address this issue, MCF-7 wild-type cells are P-gp
negative. We have con¢rmed this by Western blot analysis
using the P-gp rich MCF-7-adriamycin resistant cell line as
a positive control (data not shown). This implies that
the in£uence of PSC 833 on ceramide synthesis is independ-
ent of P-gp. Overall, the results presented herein strongly sup-
port a mechanism of action of PSC 833 that is divorced
from P-gp. The involvement of ceramide in cellular response
to anticancer agents and MDR modulators merits further
study.
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